With EU CE mark clearance for LigaSure RAS, Medtronic expands the Hugo system’s capabilities in gynaecologic and urologic ...

Medtronic announced today that it received CE mark for its LigaSure vessel sealing technology for use with its Hugo system.

Medtronic said its market-leading LigaSure technology can now be used with its Hugo soft tissue robotic surgery system in ...

Medtronic has announced the first subject enrolment in the Peripheral Onyx Liquid Embolic (PELE) trial. The study aims to ...

Medtronic's long-term dividend streak also points to a business capable of performing well over long periods. Healthcare ...

Medtronic is a diversified medical device company with a low-growth value stock position. The Hugo RAS system has the potential to drive significant growth for Medtronic in the robotic-assisted ...

Medtronic expects Hugo’s U.S. arrival to help growth rebound in the company’s surgical business. CEO Geoff Martha, at an investor event in May, ...

Hugo is already on the market in some countries, but made a slow start commercially. Medtronic cut its sales forecast in 2021, slashing the midpoint of its range from $75 million to $30 million ...

Medtronic also announced today that it submitted the Hugo RAS system to the U.S. Food and Drug Administration (FDA) for a urologic indication in the first quarter of calendar 2025.

Medtronic has been developing its robotic-assisted surgery (RAS) device, the Hugo system, for years. This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy Skip to main content ...